Drug Profile
INO 1400
Alternative Names: hTERT DNA cancer vaccine - Inovio; INO-1400Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Inovio Pharmaceuticals
- Class Cancer vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Second-line therapy or greater) in USA (IM)
- 28 Apr 2020 No recent reports of development identified for phase-I development in Solid-tumours(Monotherapy, Second-line therapy or greater) in USA (IM)
- 09 Nov 2018 novio Pharmaceuticals completes a phase I trial in Solid tumours (Second-line therapy or greater, Monotherapy) in USA (IM) (NCT02960594)